Loading
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Regular session
$5.9528
−$0.0072 · -0.12%
Regular session · ET · Market data may be delayed.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Day range
Current $5.9528
52-week range
Current $5.9528
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
69
Bullish
Risk
70
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Day range
Current $5.9528
52-week range
Current $5.9528
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 134.48M USD | 139.93M USD | 89.08M USD | 49.01M USD | 22.59M USD |
| Cost of goods sold | 31.47M USD | 40.98M USD | 35.31M USD | 27.68M USD | 18.08M USD |
| Gross profit | 103.01M USD | 98.94M USD | 53.77M USD | 21.33M USD | 4.52M USD |
| Research and development | 38.55M USD | 34.37M USD | 29.05M USD | 25.98M USD | 24.5M USD |
| Selling, general, and administrative | 112.65M USD | 101.43M USD | 74.8M USD | 58.67M USD | 32.81M USD |
| Operating expenses | 151.2M USD | 135.8M USD | 103.85M USD | 84.65M USD | 57.3M USD |
| Interest income | 2.51M USD | 9.47M USD | 6.57M USD | 1.52M USD | 54K USD |
| Interest expense | 40K USD | 21K USD | 3.31M USD | 4.95M USD | 3.68M USD |
| Depreciation and amortization | — | 3.62M USD | 4.24M USD | 4.02M USD | 3.99M USD |
| Operating income | −48.19M USD | −36.86M USD | −50.09M USD | −63.32M USD | −52.79M USD |
| Net income | −38.94M USD | −27.46M USD | −48.61M USD | −66.76M USD | −48.69M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.50
25.99% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.38M0.00%2.3T USD0.03%$376.61+0.90%
iShares Russell 2000 ETFIWM6.35M0.01%77.55B USD0.19%$289.09+0.48%
Vanguard Extended Market ETFVXF2.46M0.00%93.7B USD0.05%$237.72+0.66%
iShares Russell 2000 Value ETFIWN2.27M0.02%14.28B USD0.24%$219.65+0.31%
Vanguard Russell 2000 ETFVTWO1.34M0.01%17.4B USD0.06%$116.87+0.45%
Schwab U.S. Small-Cap ETFSCHA1.03M0.00%22.32B USD0.03%$33.7899+0.42%
iShares Micro-Cap ETFIWC855.65K0.06%1.44B USD0.60%$190.66+0.29%
Vanguard Health Care ETFVHT714.88K0.00%20.9B USD0.09%$311.16-0.04%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
